ArticleJournal of neurology2025

Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.

Hernan Inojosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.